Compare WFCF & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WFCF | INKT |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | United States |
| Employees | N/A | 15 |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.3M | 70.6M |
| IPO Year | 2006 | 2021 |
| Metric | WFCF | INKT |
|---|---|---|
| Price | $13.24 | $14.21 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 3.8K | ★ 52.7K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $20,774,416.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $40.60 | ★ N/A |
| Revenue Growth | ★ 16.69 | N/A |
| 52 Week Low | $9.69 | $6.66 |
| 52 Week High | $13.75 | $76.00 |
| Indicator | WFCF | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 55.21 | 68.03 |
| Support Level | $11.79 | $13.43 |
| Resistance Level | $13.63 | $15.99 |
| Average True Range (ATR) | 0.45 | 1.13 |
| MACD | -0.05 | 0.41 |
| Stochastic Oscillator | 61.50 | 84.32 |
Where Food Comes From Inc is a third-party food verification company conducting both on-site and desk audits to verify that claims being made about livestock, food, other high-value specialty crops and agricultural and aquaculture products are accurate. The company supports farmers, ranchers, vineyards, wineries, processors, retailers, distributors, trade associations, and restaurants with a wide variety of value-added services provided through its family of verifiers, including International Certification Services, Validus Verification Services, and others. It also provides a wide range of professional consulting services. It generates the majority of its revenue from Verification and certification services.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.